The U.S. FDA has approved Novo Nordisk's Ozempic for reducing kidney failure risk, disease progression, and death due to ...

The U.S. Food and Drug Administration (FDA) has granted approval for an expanded use of Ozempic® (semaglutide) injection, ...

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

Novo Nordisk (NVO) announced that the Food and Drug Administration has approved Ozempic to reduce the risk of kidney disease worsening, kidney ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

People with pockets of fat hidden inside their muscles are at a higher risk of dying or being hospitalised from a heart ...

News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...